Amgen is delighted to announce the launch of the

PCSK9 Competitive Grant Program

, che offrirà agli investigatori di tutto il mondo la possibilità di competere per singole sovvenzioni fino a 200,000 USD for novel research proposals that seek to advance the understanding of PCSK9 and atherosclerosis.

The program is global in reach and is open to proposals from established and junior investigators*.

The deadline for applications is Friday, Maggio 11, 2018 (11:59 pm US Pacific Time).

*Junior investigators should be within 5 years of completion of training

 

categorie: Stem Cells terapia

NBScience

organizzazione di ricerca a contratto

terapia con cellule staminali